Crossmark

A sequentially targeted and pathology-responsive nanoplatform for synergistic treatment of dry eye disease via concurrent anti-inflammation and mitochondrial ROS scavenging

Crossref DOI link: https://doi.org/10.1186/s12951-026-04365-7

Published Online: 2026-05-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Liandi

Liu, Xin

Yuan, Ying

Ke, Bilian
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82371092)

National Key Research and Development Program of China (2024YFC2510802)
License Information

Text and Data Mining valid from 2026-05-22

Version of Record valid from 2026-07-20
More Information

Article History

Received: 20 January 2026

Accepted: 29 March 2026

First Online: 22 May 2026

Declarations

Ethics approval and consent to participate: All animal experiments were performed subject to relevant guidelines and regulations and received approval from the Animal Experimental Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine (RJ2024-129B).

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below